Carl H. June

Carl H. June is widely recognized as a founder of CAR-T cell therapy and has led its translation from laboratory concept to FDA-approved therapeutics. His pioneering work demonstrated that chimeric antigen receptor-modified T cells could induce durable remissions in patients with relapsed/refractory B-cell malignancies. June's research established key principles for CAR-T cell manufacturing, persistence, and safety that continue to guide the field. His work directly led to the FDA approval of Kymriah, the first CAR-T cell therapy.

Carl H. June被公认为CAR-T细胞治疗的创始人之一，领导了该技术从实验室概念到FDA批准疗法的转化。他的开创性工作证明，嵌合抗原受体修饰的T细胞可以在复发/难治性B细胞恶性肿瘤患者中诱导持久缓解。June的研究建立了CAR-T细胞制造、持久性和安全性的关键原则，继续指导该领域的发展。他的工作直接促成了Kymriah（第一个CAR-T细胞疗法）的FDA批准。